KEVZARA® (sarilumab)

PATIENT ALERT CARD

▼ This medicine is subject to additional monitoring.

WARNING FOR HEALTHCARE PROFESSIONALS:
Please note this patient is receiving treatment with sarilumab

- This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with KEVZARA®.
- Show this card to any doctor involved in your care.

Seek medical attention immediately if you develop symptoms such as fever, sweats, chills, persistent cough, weight loss, lethargy and disinterest, or if you develop stomach-area pain that does not go away. These could be signs and symptoms of a serious infection or indicate a serious problem with the digestive tract.

Treatment with sarilumab can lower the ability of your immune system to fight infections which increases the risk of getting infections or make any infection you have worse.

- Treatment with sarilumab may increase the risk of developing low levels of white blood cells and bowel perforation.
- Talk to your doctor if you have any kind of infection, get a lot of infections, or have repeated infections.

- Talk to your doctor if you recently received or before you receive any vaccination.
- You should have been screened for tuberculosis prior to treatment with sarilumab.
- White blood cell counts will be monitored during blood tests performed before and during your treatment.
- Read the Kevzara® package leaflet for full information and instructions for use.

TREATMENT DETAILS

Sarilumab dose (every two weeks):

Start Date:

Patient's Name:

Doctor's Name:

Doctor's Phone:

Please make sure you also have a list of all your other medicines with you at any visit to a healthcare professional.

Keep this card with you for 2 months after the last KEVZARA® dose, since side effects could occur for some time after your last dose of KEVZARA®.

If you notice any side effects, talk to your doctor or pharmacist. You can also report side effects directly at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Sanofi. Tel: 0800 0902 314

SANOFI GENZYME

SAGB.SARI.17.03.0356b, September 2017